Primary reason for treatment termination
| . | BSC (n = 229), n (%) . | Tipifarnib (n = 228), n (%) . | Total (n = 457), n (%) . |
|---|---|---|---|
| Patients who terminated treatment | 221 (97) | 227 (> 99) | 448 (98) |
| Reason for termination | |||
| Progressive AML/relapse | 97 (42) | 98 (43) | 195 (43) |
| Peripheral blood counts | 37 (16) | 52 (23) | 89 (19) |
| Bone marrow examination | 50 (22) | 37 (16) | 87 (19) |
| Clinical examination | 10 (4) | 9 (4) | 19 (4) |
| Death | 70 (31) | 48 (21) | 118 (26) |
| Adverse events | 30 (13) | 25 (11) | 55 (12) |
| Progressive disease | 37 (16) | 18 (8) | 55 (12) |
| Other | 3 (1) | 5 (2) | 8 (2) |
| Subject choice | 33 (14) | 35 (15) | 68 (15) |
| Investigator decision | 16 (7) | 11 (5) | 27 (6) |
| Adverse event | 4 (2) | 26 (11) | 30 (7) |
| Complete remission | 0 | 9 (4) | 9 (2) |
| Lost to follow-up | 1 (< 1) | 0 | 1 (< 1) |
| Ongoing | 8 (3) | 1 (< 1) | 9 (2) |
| . | BSC (n = 229), n (%) . | Tipifarnib (n = 228), n (%) . | Total (n = 457), n (%) . |
|---|---|---|---|
| Patients who terminated treatment | 221 (97) | 227 (> 99) | 448 (98) |
| Reason for termination | |||
| Progressive AML/relapse | 97 (42) | 98 (43) | 195 (43) |
| Peripheral blood counts | 37 (16) | 52 (23) | 89 (19) |
| Bone marrow examination | 50 (22) | 37 (16) | 87 (19) |
| Clinical examination | 10 (4) | 9 (4) | 19 (4) |
| Death | 70 (31) | 48 (21) | 118 (26) |
| Adverse events | 30 (13) | 25 (11) | 55 (12) |
| Progressive disease | 37 (16) | 18 (8) | 55 (12) |
| Other | 3 (1) | 5 (2) | 8 (2) |
| Subject choice | 33 (14) | 35 (15) | 68 (15) |
| Investigator decision | 16 (7) | 11 (5) | 27 (6) |
| Adverse event | 4 (2) | 26 (11) | 30 (7) |
| Complete remission | 0 | 9 (4) | 9 (2) |
| Lost to follow-up | 1 (< 1) | 0 | 1 (< 1) |
| Ongoing | 8 (3) | 1 (< 1) | 9 (2) |
AML indicates acute myeloid leukemia; and BSC, best supportive care, including hydroxyurea.